December 16, 2016
1 min read
Save

EMA accepts application for Oxervate for treatment of neurotrophic keratitis

A registration application for Oxervate eye drops for the treatment of moderate and severe neurotrophic keratitis in adults has been accepted by the European Medicines Agency, according to a Dompé press release.

The acceptance allows Oxervate, which was designated as an orphan drug by the EMA’s committee for Orphan Medicinal Products in 2015, to begin a scientific review procedure for marketing authorization, the release said.

The drug will most likely be assessed at an accelerated rate designed for severe conditions that currently have no valid treatment options.